GUADALAJARA, MEXICO — Physical activity is important for patients with diabetes. Engaging in healthy exercise requires a personal medical assessment that identifies the type of training […]

TOPLINE: Nearly four in every 1000 youths and five in every 1000 adults in the United States reported having type 1 diabetes (T1D) in the National […]

TOPLINE: Insulin resistance and obesity in adolescents may lead to increased abdominal fibrogenesis, impairing the capacity of the abdominal subcutaneous adipose tissue (SAT) to store lipids, […]

TOPLINE: Tirzepatide vs basal insulins led to greater improvements in A1c and postprandial glucose (PPG) levels in patients with type 2 diabetes (T2D), regardless of different […]

(Reuters) – Four doses of Eli Lilly’s diabetes drug Mounjaro would remain in tight supply through 2024 due to soaring demand, the U.S. Food and Drug […]

TOPLINE: Data from 12 studies suggest that rates of non-persistence to basal insulin treatment among people with type 2 diabetes (T2D) are 21%, 34%, and 37% […]

Artificial intelligence (AI) has identified two plant-based bioactive compounds with potential as glucagon-like-peptide-1 receptor (GLP-1R) agonists for weight loss as possible alternatives to pharmaceutical weight-loss drugs, […]

Eli Lilly and Company, a manufacturer of tirzepatide (marketed as Mounjaro for type 2 diabetes and Zepbound for obesity), has launched a direct-to-consumer (DTC) advertising campaign […]

Can brown fat tissue be targeted for fat burning? Current findings on this topic were presented at the 67th German Congress of Endocrinology. Some statistics highlighted […]